CancerDrs

Ovarian Cancer clinical trials in Washington

45 actively recruiting ovarian cancer trials at 35 sites across Washington.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Washington:
  • Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
  • FHCC Overlake — Bellevue, Washington
  • PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
  • Providence Regional Cancer System-Centralia — Centralia, Washington
  • Swedish Cancer Institute-Edmonds — Edmonds, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…

Sponsor: NRG Oncology
NCT ID: NCT06580314
Sites in Washington:
  • Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
  • PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
  • Providence Regional Cancer System-Centralia — Centralia, Washington
  • Swedish Cancer Institute-Edmonds — Edmonds, Washington
  • Providence Regional Cancer Partnership — Everett, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Washington:
  • Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
  • Overlake Medical Center — Bellevue, Washington
  • PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
  • Highline Medical Center-Main Campus — Burien, Washington
  • Providence Regional Cancer System-Centralia — Centralia, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part o…

Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Sites in Washington:
  • Seattle Children's Hospital — Seattle, Washington
  • Fred Hutchinson Cancer Center — Seattle, Washington
  • University of Washington Medical Center - Montlake — Seattle, Washington
  • Providence Sacred Heart Medical Center and Children's Hospital — Spokane, Washington
  • Madigan Army Medical Center — Tacoma, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A enrolls participants with p…

Sponsor: Eli Lilly and Company
NCT ID: NCT07213804
Sites in Washington:
  • Swedish Cancer Institute - Edmonds — Edmonds, Washington
  • Swedish Medical Center — Seattle, Washington
  • Fred Hutchinson Cancer Center — Seattle, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

Sponsor: Incyte Corporation
NCT ID: NCT07214779
Sites in Washington:
  • Fred Hutchinson Cancer Center — Seattle, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice…

Sponsor: Genelux Corporation
NCT ID: NCT05281471
Sites in Washington:
  • Providence Sacred Heart Medical Center & Children's Hospital — Spokane, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

Sponsor: Imunon
NCT ID: NCT06915025
Sites in Washington:
  • Providence Sacred Heart Medical Center & Children's Hospital — Spokane, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Washington:
  • Swedish Cancer Institute-Edmonds — Edmonds, Washington
  • Swedish Cancer Institute-Issaquah — Issaquah, Washington
  • Providence Regional Cancer System-Lacey — Lacey, Washington
  • Valley Medical Center — Renton, Washington
  • Swedish Medical Center-First Hill — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite tre…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554328
Sites in Washington:
  • Swedish Cancer Institute-Edmonds — Edmonds, Washington
  • Swedish Cancer Institute-Issaquah — Issaquah, Washington
  • Providence Regional Cancer System-Lacey — Lacey, Washington
  • Valley Medical Center — Renton, Washington
  • Swedish Medical Center-First Hill — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05112601
Sites in Washington:
  • Swedish Cancer Institute-Edmonds — Edmonds, Washington
  • Swedish Cancer Institute-Issaquah — Issaquah, Washington
  • Fred Hutchinson Cancer Center — Seattle, Washington
  • Swedish Medical Center-First Hill — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with fo…

Sponsor: AbbVie
NCT ID: NCT06890338
Sites in Washington:
  • Providence Sacred Heart Medical Center & Children'S Hospital /ID# 274585 — Spokane, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conduct…

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT05128825
Sites in Washington:
  • Site 0323 - Compass Oncology — Vancouver, Washington
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…

Sponsor: Genmab
NCT ID: NCT05579366
Sites in Washington:
  • Swedish Cancer Institute — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine …

Sponsor: AbbVie
NCT ID: NCT07059845
Sites in Washington:
  • Virginia Mason Hospital and Medical Center /ID# 277259 — Seattle, Washington
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Washington:
  • Seattle Children's Hospital — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on patients who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the st…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06787612
Sites in Washington:
  • Swedish Cancer Institute — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…

Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Washington:
  • Wenatchee Hospitals and Clinics — Wenatchee, Washington
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmaco…

Sponsor: Incyclix Bio
NCT ID: NCT05735080
Sites in Washington:
  • Northwest Medical Specialties, PLLC — Tacoma, Washington
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…

Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Washington:
  • Fred Hutchinson Cancer Center — Seattle, Washington
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).

Sponsor: Immatics US, Inc.
NCT ID: NCT03686124
Sites in Washington:
  • Fred Hutchinson Cancer Center — Seattle, Washington
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT04590326
Sites in Washington:
  • Seattle Cancer Care Alliance at South Lake Union - G3630 — Seattle, Washington
View on ClinicalTrials.gov →

Showing 25 of 45 trials with sites in Washington. See all ovarian cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07